Shots:
- BioNTech has entered into a definitive purchase agreement to acquire CureVac in an all-stock transaction, strengthening its mRNA tech & capabilities
- As per the deal, each CureVac share will be exchanged for ~$5.46 in BioNTech ADSs, implying a total equity value of ~$1.25B, with a collar-adjusted exchange ratio (0.04318 if BioNTech’s 10-day VWAP >$126.55; 0.06476 if <$84.37), resulting in CureVac shareholders owning 4–6% of BioNTech; closing expected in 2025
- CureVac will become a wholly owned subsidiary of BioNTech, which will also integrate CureVac’s advanced research & manufacturing facility in Tübingen as part of the reorganization plan
Ref: CureVac | Image: CureVac| Press Release
Related News:- Sanofi to Acquire Blueprint Medicines for ~$9.5B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
